Companies / Rapport Therapeutics, Inc. / Activity
Activity — Rapport Therapeutics, Inc.
31 moves.
| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | Yeleswaram Krishnaswamy Executive | Sell | Common Stock | $303.4K | -10K -3.41% | 286,876 0.60% of shares | medium |
| Jan 15, 2026 | Bredt David Executive | Sell | Common Stock | $222.7K | -8K -2.05% | 395,775 0.82% of shares | medium |
| Mar 30, 2026 | Gault Cheryl Executive | Sell | Common Stock | $200.8K | -7K -4.21% | 162,753 0.34% of shares | medium |
| Dec 31, 2025 | Bredt David Executive | Sell | Common Stock | $197.3K | -7K -1.60% | 404,075 0.84% of shares | medium |
| Feb 17, 2026 | Bredt David Executive | Sell | Common Stock | $156.3K | -5K -1.37% | 389,275 0.81% of shares | medium |
| Jan 20, 2026 | Ceesay Abraham CEO | Sell | Common Stock | $152.3K | -6K -1.03% | 562,080 1.17% of shares | medium |
| Jan 20, 2026 | Ceesay Abraham CEO | Sell | Common Stock | $132.7K | -5K -16.45% | 25,812 0.05% of shares | medium |
| Feb 18, 2026 | Ceesay Abraham CEO | Sell | Common Stock | $103.2K | -4K -0.63% | 558,528 1.16% of shares | medium |
| Feb 18, 2026 | Ceesay Abraham CEO | Sell | Common Stock | $86.6K | -3K -11.56% | 22,829 0.05% of shares | low |
| Dec 31, 2025 | Yeleswaram Krishnaswamy Executive | Sell | Common Stock | $85.3K | -3K -0.95% | 296,991 0.62% of shares | low |
| Mar 30, 2026 | Gault Cheryl Executive | Sell | Common Stock | $81.1K | -3K -1.74% | 159,914 0.33% of shares | low |
| Feb 18, 2026 | Ceesay Abraham CEO | Sell | Common Stock | $68.0K | -2K -0.41% | 556,247 1.16% of shares | low |
| Feb 17, 2026 | Bredt David Executive | Sell | Common Stock | $65.1K | -2K -0.57% | 387,075 0.81% of shares | low |
| Feb 18, 2026 | Ceesay Abraham CEO | Sell | Common Stock | $62.6K | -2K -9.20% | 20,729 0.04% of shares | low |
| Mar 5, 2026 | Gault Cheryl Executive | Sell | Common Stock | $58.3K | -2K -1.17% | 169,914 0.35% of shares | low |
| Feb 17, 2026 | Bredt David Executive | Sell | Common Stock | $25.2K | -900 -0.23% | 394,675 0.82% of shares | low |
| Feb 19, 2026 | Bredt David Executive | Exercise | Common Stock | $10.8K | +6K +1.55% | 393,075 0.82% of shares | low |
| Jan 15, 2026 | Bredt David Executive | Sell | Common Stock | $5.5K | -200 -0.05% | 395,575 0.82% of shares | low |
| Jun 10, 2026 | Perez Robert J Director | Grant | Stock Option (Right to Buy) | — | +15K | 15,200 0.03% of shares | low |
| Jun 10, 2026 | Healy James Director | Grant | Stock Option (Right to Buy) | — | +15K | 15,200 0.03% of shares | low |
| Jun 10, 2026 | Paul Steven M Director | Grant | Stock Option (Right to Buy) | — | +15K | 15,200 0.03% of shares | low |
| Jun 10, 2026 | Maraganore John Director | Grant | Stock Option (Right to Buy) | — | +15K | 15,200 0.03% of shares | low |
| Feb 19, 2026 | Bredt David Executive | Exercise | Stock Options (Right to Buy) | — | -6K -6.38% | 88,080 0.18% of shares | low |
| Feb 2, 2026 | Yeleswaram Krishnaswamy Executive | Grant | Stock Option (Right to Buy) | — | +120K | 120,000 0.25% of shares | low |
| Feb 2, 2026 | Bredt David Executive | Grant | Stock Option (Right to Buy) | — | +103K | 103,000 0.21% of shares | low |
| Dec 31, 2025 | Bredt David Executive | Grant | Common Stock | — | -18K -4.20% | 410,642 0.86% of shares | low |
| Dec 31, 2025 | Yeleswaram Krishnaswamy Executive | Grant | Common Stock | — | +9K +3.09% | 299,831 0.62% of shares | low |
| Feb 2, 2026 | Gault Cheryl Executive | Grant | Stock Option (Right to Buy) | — | +132K | 132,000 0.28% of shares | low |
| Feb 2, 2026 | Sevigny Jeffrey Executive | Grant | Stock Option (Right to Buy) | — | +130K | 130,000 0.27% of shares | low |
| Feb 2, 2026 | Ceesay Abraham CEO | Grant | Stock Option (Right to Buy) | — | +428K | 428,000 0.89% of shares | low |
| Feb 2, 2026 | Ignelzi Troy A. Executive | Grant | Stock Option (Right to Buy) | — | +148K | 148,000 0.31% of shares | low |